Stereoselective propranolol metabolism in two drug induced rat hepatic microsomes

World Journal of Gastroenterology

Volumn 6, Issue 1, 2000, Pages 74-78

  Li, X ^a,b   Zeng, S ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA NAPHTHOFLAVONE; CYTOCHROME P450; PHENOBARBITAL; PROPRANOLOL;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; LIVER MICROSOME; NONHUMAN; RAT; STEREOCHEMISTRY;

EID: 0033973693     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v6.i1.74     Document Type: Article

References (26)

1. Walle T, Oatis JE Jr, Walle UK, Knapp DR. New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos, 1982;10:122-127
2. Bargar EM, Walle UK, Bai SA, Walle T. Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography, and gas chromatography-mass spectrometry techniques. Drug Metab Dispos, 1983;11:266-272
3. Stark G, Stark U, Lueger A, Bertuch H, Pilger E, Pietsch B, Tritthart HA, Lindner W. The effects of the propranolol enantiomers on the intracardiac electrophysiological activities of Langendorff perfused hearts. Basic Res Cardiol, 1989;84:461-468
4. Masubuchi Y, Yamamoto LA, Uesaka M, Fujita S, Narimatsu S, Suzuki T. Substrate stereoselectivity and enantiomer/enantiomer interaction in propranolol metabolism in rat liver microsomes. Biochem Pharmacol, 1993;46:1759-1765
5. Thompson JA, Hull JE, Norris KJ. Glucuronidation of propranolol and 4′-hydroxypropranolol. Substrate specificity and stereoselectivity of rat liver microsomal glucuronyltransferases. Drug Metab Dispos, 1981;9: 466-471
6. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkanen U, Anttila M, Sundqvist H. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol. Br J Clin Pharmacol, 1980;9:399 -405
7. Hickey PL, McLean AJ, Angus PW, Choo EF, Morgan DJ. Increased sensitivity of propranolol clearance to reduced oxygen delivery in the isolated perfused cirrhotic rat liver. Gastroenterology, 1996;111:1039 -1048
8. Otton SV, Gillam EM, Lennard MS, Tucker GT, Woods HF. Propranolol oxidation by human liver microsomes - the use of cumene hydroperoxide to probe isoenzyme specificity and regio-and stereoselectivity. Br J Clin Pharmacol, 1990;30:751-760
9. Ishida R, Obara S, Masubuchi Y, Narimatsu S, Fujita S, Suzuki T. Induction of propranolol metabolism by the azo dye sudan III in rats. Biochem Pharmacol, 1992;43:2489-2492
10. Nelson WL, Bartels MJ. Stereoselectivity in the aromatic hydroxylation of propranolol in the rat: use of deuterium labeling and pseudoracemic mixtures. Drug Metab Dispos, 1984;12:382-384
11. Gibbson GG, Shett P. Introduction to drug metabolism (Second Edition). London: Blackie Academic & Professional, 1994:217-221
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Bio Chem, 1951;193: 265-275
13. Bachmann K, Sanyal G, Potter J, Schiavone R, Loch J. In vivo evidence that theophylline is metabolized principally by CYP1A in rats. Pharmacology, 1993;47:1-7
14. Takahashi N, Harttig U, Williams DE, Bailey GS. The model Ah-receptor agonist beta-naphthoflavone inhibits aflatoxin B1-DNA binding in vivo in rainbow trout at dietary levels that do not induce CYP1A enzymes. Carcinogenesis, 1996;17:79-87
15. Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos, 1995;23:1253-1262
16. ChangTK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabololism. J Pharmacol Exp Ther, 1995;274:270-275
17. Nims RW, Lubet RA, Diwan BA, Mellini DW, Utermahlen WE Jr, Thomas PE. Hepatic cytochrome P450 2B induction by ethyl/phenyl-substituted congeners of phenobarbital in the B6C3F1 mouse. J Biochem Toxicol, 1994;9:269-278
18. Capdevila JH, Karara A, Waxman DJ, Martin MV, Falck JR, Guenguerich FP. Cytochrome P-450 enzyme-specific control of the regio-and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase. J Biol Chem, 1990;265:10865-10871
19. Fujita S, Umeda S, Funae Y, Imaoka S, Abe H, Ishida R, Adachi T, Masuda M, Kazusaka A, Suzuki T. Regio-and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver. J Pharmacol Exp Ther, 1993;264:226-233
20. Ching MS, Bichara N, Blake CL, Ghabrial H, Tukey RH, Smallwood RA. Propranolol 4-and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metab Dispos, 1996;24:692-694
21. Brosen K. Drug interactions and the cytochrome P450 system. The role of cytochrome P4501A2. Clin Pharmacokinet, 1995;29(Suppl 1):20 -25
22. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos, 1994;22:909-915
23. Rowland K, Ellis SW, Lennard MS, Tucker GT. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes. Br J Clin Pharmacol, 1996;42:390-393
24. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers - N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol, 1995;39:421-431
25. Narimatsu S, Mochida M, Matsumoto T, Masubuchi Y, Horie T, Nagata K, Funae Y, Cho AK, Suzuki T. Cytochrome P450 enzymes involved in the enhancement of propranolol N-desisopropylation after repeated administration of propranolol in rats. Chem Biol Interact, 1996;101:207-224
26. Masubuchi Y, Yamamoto LA, Uesaka M, Fujita S, Narimatsu S, Suzuki T. Substrate stereoselectivity and enantiomer/enantiomer interaction in propranolol metabolism in rat liver microsomes. Biochem Pharmacol, 1993;46:1759-1765